Histone-lysine N-methyltransferase 2A/WDR5
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Histone-lysine N-methyltransferase 2A/WDR5 as ChEMBL target CHEMBL3883320, mapped to UniProt P61964. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Why Histone-lysine N-methyltransferase 2A/WDR5 matters
Histone-lysine N-methyltransferase 2A/WDR5 is reviewed as WD repeat-containing protein 5 (UniProt P61964); the current evidence base includes 5 approved drugs, 99 compounds, and 38 assays, with lead potency reaching pChEMBL 9.1.
WD repeat-containing protein 5 Sequence length is 334 aa.
Review this target as Histone-lysine N-methyltransferase 2A/WDR5, mapped to UniProt P61964. ChEMBL maps the protein component as WD repeat-containing protein 5. Sequence length is 334 aa.
Protein source · UniProt accession via ChEMBL component mappingDisease relevance is not yet populated for this evidence card.
This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target recordChEMBL currently tracks 5 approved drugs, 99 compounds, and 38 assays for this target. The dominant activity type is IC50. CHEMBL3798088 is the current potency anchor at pChEMBL 9.1.
Use CHEMBL3798088 as the tractability anchor when discussing potency (pChEMBL 9.1).
Activity source · ChEMBL 36 via Core EngineStart with the right source
Pick the first block or linked source that matches the review question in front of you.
Start with the review rationale when you need to explain why Histone-lysine N-methyltransferase 2A/WDR5 matters before drilling into raw source blocks.
Jump to Review RationaleGo back to the target snapshot when you need the naming and mapping contract behind UniProt P61964, not just the summarized rationale.
Open Protein ContextUse the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL3798088
|
9.1 | IC50 | — |
|
|
No preferred name
CHEMBL4588661
|
8.2 | IC50 | — |
|
|
No preferred name
CHEMBL5562523
|
8.1 | IC50 | — |
|
|
No preferred name
CHEMBL5573350
|
8.0 | IC50 | — |
|
|
No preferred name
CHEMBL5579746
|
8.0 | IC50 | — |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
RABEPRAZOLE
CHEMBL1219
|
1999 |